Ipatasertib
Ipatasertib
Ipatasertib (pronounced as i-pa-ta-ser-tib) is a small molecule inhibitor of the serine/threonine protein kinase AKT (Protein Kinase B) that is currently under investigation for its potential use in the treatment of various types of cancer.
Etymology
The name "Ipatasertib" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature. It is a systematic name that follows the rules and guidelines set by the IUPAC for naming new chemical entities.
Mechanism of Action
Ipatasertib works by inhibiting the AKT signaling pathway, which is often overactive in many types of cancer cells. By blocking this pathway, it can help to stop or slow down the growth of cancer cells.
Clinical Trials
Ipatasertib is currently being studied in several clinical trials for its potential use in treating various types of cancer, including breast cancer, prostate cancer, and lung cancer.
Related Terms
- AKT: A protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Clinical trial: Research studies that aim to find better ways to prevent, screen for, diagnose, or treat disease.
- Breast cancer: A type of cancer that forms in the cells of the breasts.
- Prostate cancer: A type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.
- Lung cancer: A type of cancer that begins in the lungs.
External links
- Medical encyclopedia article on Ipatasertib
- Wikipedia's article - Ipatasertib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski